Zacks Rank #1 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
BRLI: 31.82 (+0.55), AXGN: 3.85 (+0.17), AZPN: 36.69 (+0.28), ARQL: 1.15 (+0.01), ADUS: 23.80 (-0.19)
Weakness Seen in La Jolla Pharmaceutical (LJPC): Stock Tumbles 17.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 7:41AM CST
La Jolla Pharmaceutical aw a big move last session, as the company’s shares fell by nearly 18% which reversed the trend for the company.
LJPC: 16.35 (-0.10), ARQL: 1.15 (+0.01)
PTC Therapeutics, Inc. (PTCT) in Focus: Stock Gains 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 8:32AM CST
PTC Therapeutics, Inc. (PTCT) was a big mover last session, as the company saw its shares rise more than 5% on the day.
LGI: 16.17 (-0.01), ARQL: 1.15 (+0.01), PTCT: 51.66 (+0.76), IG: 9.11 (-0.01)
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
DXLG: 5.33 (+0.09), GPN: 81.93 (+0.26), AXGN: 3.85 (+0.17), ARQL: 1.15 (+0.01), ELNK: 4.30 (-0.05)
Liquidity Services, Inc. to Conduct Auction of High-Value Life Sciences Equipment
PR Newswire - Tue Dec 09, 7:30AM CST
Liquidity Services, Inc. (NASDAQ:LQDT) a global solution provider in the reverse supply chain with the world's largest marketplace for business surplus, is conducting an online auction for surplus equipment including biotech, research and development, and lab equipment not utilized in ArQule, Inc's (NASDAQ:ARQL) Woburn, MA facility. The assets consist of high-value, late-model analytical equipment including high performance liquid chromatograph systems, imaging systems, mass spectrometers, NMR systems, pharmaceutical processing equipment and general lab equipment.
LQDT: 8.19 (-0.19), ARQL: 1.15 (+0.01)
ChemoCentryx Drug Gets Orphan Designation in Europe - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 5:07PM CST
Positive news flowed in for ChemoCentryx, Inc., (CCXI) when it announced that the European Commission has granted orphan medicinal product designation to its pipeline candidate CCX168.
VRX: 140.33 (-0.22), ARQL: 1.15 (+0.01), SCMP: 13.75 (+0.44), CCXI: 6.64 (-0.04)
Stock to Watch: Arqule Up 10.5% (ARQL)
Comtex SmarTrend(R) - Thu Dec 04, 12:42PM CST
Arqule (NASDAQ:ARQL) is one of today's best performing low-priced stocks, up 10.5% to $1.37 on 1.0x average daily volume. Arqule has traded 352,000 shares thus far today, vs. average volume of 342,000 shares per day. The stock has outperformed the Dow (10.5% to the Dow's 0.0%) and outperformed the S&P 500 (10.5% to the S&P's 0.0%) during today's trading.
ARQL: 1.15 (+0.01)
Can the Uptrend Continue for ArQule (ARQL)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 5:36AM CST
Can the Uptrend Continue for ArQule (ARQL)?
ARQL: 1.15 (+0.01)
Insider Trading Alert - ITG, CDXS And ARQL Traded By Insiders
at The Street - Fri Nov 21, 1:45PM CST
Stocks with insider trader activity include ITG, CDXS and ARQL
ITG: 20.72 (-0.40), ARQL: 1.15 (+0.01), CDXS: 2.45 (-0.03)
ArQule (ARQL) Shows Strength: Stock Adds 6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 8:39AM CST
ArQule Inc. (ARQL) was a big mover last session, as its shares rose nearly 6% on the day.
DRTX: 24.16 (+0.41), LCI: 42.29 (+1.79), ARQL: 1.15 (+0.01), BIOD: 1.36 (-0.04)
Traders Get Bullish on Shares of Arqule, Shares Up 6.0% (ARQL)
Comtex SmarTrend(R) - Mon Nov 17, 12:01PM CST
Arqule (NASDAQ:ARQL) is one of today's best performing low-priced stocks, up 6.0% to $1.24 on 2.3x average daily volume. Thus far today, Arqule has traded 663,000 shares, vs. average volume of 290,000 shares per day. The stock has outperformed the Dow (6.0% to the Dow's -0.1%) and outperformed the S&P 500 (6.0% to the S&P's -0.2%) during today's trading.
ARQL: 1.15 (+0.01)
Sucampo-Takeda Sue Dr. Reddy's for Amitiza Patent Violation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 3:30PM CST
Sucampo Pharmaceuticals, Inc. (SCMP) and partner Takeda Pharmaceutical Company Limited filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Dr. Reddy's Laboratories (RDY).
JAZZ: 165.33 (+1.83), ARQL: 1.15 (+0.01), SCMP: 13.75 (+0.44), RDY: 49.58 (-0.10)
ArQule Announces Data Presentations with Pipeline Products to Be Featured at 26th EORTC-NCI-AACR Symposium
Business Wire - Thu Nov 13, 7:00AM CST
ArQule, Inc. (Nasdaq: ARQL) today announced that eight presentations of clinical and pre-clinical data on three early clinical-stage product candidates will take place during the 26th EORTC-NCI-AACR Symposium to be held November 18-21, 2014 in Barcelona, Spain.
ARQL: 1.15 (+0.01)
ArQule (ARQL) Catches Eye: Stock Jumps 10.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:30AM CST
ArQule Inc. (ARQL) was a big mover last session, as the company saw its shares rise over 10% on the day.
ACRX: 6.61 (+0.06), AUXL: 34.40 (+0.18), ADHD: 4.00 (+0.24), ARQL: 1.15 (+0.01)
ArQule Announces Collaboration with NIH for Clinical Development of ARQ 092 in Proteus Syndrome
Business Wire - Tue Nov 11, 7:00AM CST
ArQule, Inc. (NASDAQ: ARQL) today announced an agreement with the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH) providing for the clinical development of ARQ 092, an orally available, selective small molecule inhibitor of AKT, in Proteus syndrome, a rare disease characterized by overgrowth of the skeleton, skin, adipose tissue and central nervous system.
ARQL: 1.15 (+0.01)
Germ Cell Tumors - Pipeline Review, H2 2014 - Overivew of 3 Companies & 6 Drug Profiles
M2 - Tue Nov 11, 3:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/29xpmk/germ_cell_tumors) has announced the addition of the "Germ Cell Tumors - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Germ Cell Tumors, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Germ Cell Tumors and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ArQule, Inc. - Philogen S.p.A. - Tolero Pharmaceuticals, Inc. Drug Profiles - alvocidib hydrochloride - tivantinib - KML-001 - Cell Therapy 1 for Oncology - Small Molecules to Inhibit Tubulin for Oncology - F8IL-4 For more information visit http://www.researchandmarkets.com/research/29...ell_tumors
ARQL: 1.15 (+0.01)
ArQule's (ARQL) CEO Paolo Pucci on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 2:29PM CST
ARQL: 1.15 (+0.01)
ArQule affirms guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:33AM CST
ARQL: 1.15 (+0.01)